Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

This study is testing a combination of oral paclitaxel (a chemotherapy pill) with subcutaneous (under-the-skin injection) versions of pertuzumab and trastuzumab — targeted antibody drugs — given before surgery in people with HER2-positive breast cancer. HER2-positive means the cancer cells have higher than normal levels of a protein that drives their growth. The goal is to shrink the tumor before surgery. **You may be eligible if...** - You are 18 to 70 years old - You have been diagnosed with HER2-positive invasive breast cancer (confirmed by biopsy) at a stage that can be treated before surgery - Your heart function is normal or near normal (ejection fraction of 50% or higher) - You are in good general health (ECOG 0 or 1) - You have not previously been treated for breast cancer **You may NOT be eligible if...** - You have had a prior invasive breast cancer or have inflammatory breast cancer - You have already had a biopsy that removed the main tumor mass - You have a history of severe allergic reactions to any of the study drugs - You have had a heart attack, stroke, or uncontrolled high blood pressure in the past 6 months - You have conditions that would prevent you from swallowing oral medication (e.g., bowel obstruction, Crohn's disease) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.